

RECEIVED
CENTRAL FAX CENTER

MAY 04 2010

Attorney's Docket No. 20674-0008US1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Michael Martin
Appl No.: 10/598,671
Filed: September 7, 2006
For: Methods and Compositions Related to Regulation of Cytokine Production by
Glycogen Synthase Kinase 3 (Gsk-3)

Confirmation No.: 8699
Group Art Unit: 1616
Examiner: Pak, John D.

May 4, 2010

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the Office Action dated March 4, 2010. Additionally provided is a signed and executed Power of Attorney and Statement under 37 CFR 3.37(b).

MM01/20674-0008US1

In re: Michael Martin
Appl No.: 10/598,671
Filed: Sept. 7, 2006
Page 2

RECEIVED
CENTRAL FAX CENTER
MAY 04 2010

RESPONSE AND ELECTION

This is in response to the Office Action dated March 4, 2010, in which the Examiner has required election among the restrictions between:

Group I, Claims 1-10, 12-14, 16-17 (in part) drawn to an effective amount of lithium;

Group II, Claims 1-9, 11-16, 18 (in part) drawn to an effective amount of SB216763;

Group III, Claims 1-9, 13, and 15-16 (in part) drawn to an effective amount of a substance that is not lithium or SB216763;

Group IV, Claims 19-21, 23 (in part) drawn to an effective amount of an agent that inhibits GSK-3 in a subject;

Group V, Claims 19-20, 12-14, 16-17 (in part) drawn to an effective amount of an agent that inhibits GSK-3 in culture;

Group VI, Claims 24-26 (in part) drawn to systemic lupus erythematosus;

Group VII, Claims 24-26 (in part) drawn to Hashimoto's disease;

Group VIII, Claims 24-26 (in part) drawn to rheumatoid arthritis;

Group IX, Claims 24-26 (in part) drawn to graft-versus-host disease;

Group X, Claims 24-26 (in part) drawn to Sjögren's syndrome;

Group XI, Claims 24-26 (in part) drawn to pernicious anemia;

Group XII, Claims 24-26 (in part) drawn to Addison's disease;

Group XIII, Claims 24-26 (in part) drawn to scleroderma;

Group XIV, Claims 24-26 (in part) drawn to Goodpasture's syndrome;

Group XV, Claims 24-26 (in part) drawn to Crohn's disease, inflammatory bowel disease, or ulcerative colitis;

Group XVI, Claims 24-26 (in part) drawn to autoimmune hemolytic anemia;

Group XVII, Claims 24-26 (in part) drawn to myasthenia gravis;

Group XVIII, Claims 24-26 (in part) drawn to multiple sclerosis;

Group XIX, Claims 24-26 (in part) drawn to Basedow's disease;

Group XX, Claims 24-26 (in part) drawn to thrombopenia purpura;

Group XXI, Claims 24-26 (in part) drawn to insulin dependent diabetes mellitus;

Group XXII, Claims 24-26 (in part) drawn to allergy;

In re: Michael Martin
Appl No.: 10/598,671
Filed: Sept. 7, 2006
Page 3

Group XXIII, Claims 24-26 (in part) drawn to asthma;
Group XXIV, Claims 24-26 (in part) drawn to cancer;
Group XXV, Claims 24-26 (in part) drawn to cardiomyopathy; and
Group XXVI, Claims 24-26 (in part) drawn to transplantation and implantation;

Applicant hereby elects without traverse to prosecute the claims of Group I, Claims 1-10, 12-14, 16-17 (in part) drawn to administering an effective amount of lithium, and expressly reserves the right to file divisional applications or take such other appropriate measures deemed necessary to protect the inventions in the remaining claims.

Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned attorney so that further examination of this application can be expedited.

It is not believed that extensions of time or fees are required, beyond those which may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration, such extensions are hereby petitioned under 37 CFR § 1.136(a).

Respectfully submitted,



C. Allen Black, Esq.
Registration No. 53,835

THE LAW OFFICE OF C. ALLEN BLACK, PH.D.
1579 Montgomery Rd.
Allison Park, PA 15101
Tel Office (412) 908-3268
Fax Office (412) 318-4815